1NKEMIA Logo

1NKEMIA

A tech group providing R&D, services, training, and investment for life sciences industries.

IKM | BME Growth

Overview

Corporate Details

ISIN(s):
ES0156303002
LEI:
959800QRRHKJ6C8MW495
Country:
Spain
Address:
C/Alvarez de Castro 63, 08100 Mollet del Vallès
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

1NKEMIA IUCT Group S.A., founded in 1997, is a technology group focused on the generation and commercial exploitation of knowledge for the life sciences sector. The company provides open R&D, technological services, and training to the chemical, pharmaceutical, biotechnological, cosmetic, and nutraceutical industries. Functioning as a business incubator and investment vehicle, 1NKEMIA actively acquires and holds stakes in high-tech SMEs. The group also manages the 'Fondo Capital Conocimiento' (Knowledge Capital Fund) to foster entrepreneurship and support the development of innovative technologies and startups.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all 1NKEMIA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for 1NKEMIA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for 1NKEMIA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-05-26 Björn Zethraeus Other Other 6,646 66,460,000.00 SEK
2025-05-24 Anders Nilsson Other Other 10,000 326,900.00 SEK
2025-05-23 marius balger Other Sell 45,000 534,150.00 SEK
2025-05-23 Todd Heringer Other Other 150,000 N/A
2025-05-22 Klaudija Cavala Other Other 100,000 22,000.00 SEK
2025-05-20 Gionata La Torre Other Buy 31,182 951,051.00 SEK
2025-05-20 Karl-Emil Engström Other Sell 5,000 279,350.00 SEK
2025-05-20 Christina Thérèse Hersch Fagerberg Other Sell 1,000 55,870.00 SEK
2025-05-20 Gionata La Torre Other Buy 31,182 N/A
2025-05-19 Erik Gjötterberg Other Other 15,000 311,550.00 SEK

Peer Companies

ProQR Therapeutics N.V. Logo
Biotech developing RNA-editing therapies for genetic disorders using the body's own enzymes.
United States of America
PRQR
Prostatype Genomics AB Logo
Provides a genetic test to assess prostate cancer aggressiveness and guide treatment choices.
Sweden
PROGEN
Protagenic Therapeutics, Inc.\new Logo
Developing novel peptide drugs to treat stress-related neuropsychiatric & CNS disorders.
United States of America
PTIX
Protara Therapeutics, Inc. Logo
Clinical-stage biotech developing cell therapies for cancer and rare diseases.
United States of America
TARA
PROTEINA CO.,LTD. Logo
A biotech firm specializing in proteomics for drug discovery and diagnostics in oncology.
South Korea
468530
PROTEOME SCIENCES PLC Logo
CRO providing proteomics services & TMT® tags to biopharma for drug discovery & biomarkers.
United Kingdom
PRM
PROTHENA CORP PUBLIC LTD CO Logo
Advancing antibody-based therapies for neurodegenerative and rare amyloid diseases.
United States of America
PRTA
PROVEXIS PLC Logo
Develops & licenses Fruitflow®, a patented ingredient for heart health in food & supplements.
United Kingdom
PXS
Psomagen, Inc. Logo
A CRO providing multiomics services & data analysis for academic, biotech, and pharma researchers.
United States of America
950200
Psych Capital Plc Logo
A life sciences firm developing psilocybin treatments for anorexia and mental health conditions.
United Kingdom
PSY

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.